Zhou Ting, Hong Shaodong, Hu Zhihuang, Hou Xue, Huang Yan, Zhao Hongyun, Liang Wenhua, Zhao Yuanyuan, Fang Wenfeng, Wu Xuan, Qin Tao, Zhang Li
Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651# Dongfeng East Road, Guangzhou, China, 510060.
Tumour Biol. 2015 Jan;36(1):337-43. doi: 10.1007/s13277-014-2623-4. Epub 2014 Sep 26.
Recent studies have shown the combination of C-reactive protein (CRP) and albumin (The modified Glasgow Prognostic Score, mGPS) had prognostic value in some solid tumors. However, no studies have examined its prognostic role in small-cell lung cancer (SCLC) patients. In this retrospective study, 460 consecutive SCLC patients were screened. Eligible patient was assigned a mGPS of 0, 1, or 2 based on pre-treatment plasma CRP and albumin (0: CRP ≤ 10 mg/L; 1: CRP >10 mg/L and albumin ≥ 35 g/L; 2: CRP > 10 mg/L and albumin < 35 g/L). Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors for SCLC. A total of 359 patients were analyzed. The mGPS of 0, 1, and 2 was assigned to 66.3, 30.6, and 3.1 % of total patients. For patients with mGPS of 0, 1, and 2, median overall survival (OS) was 30.4, 28.2, and 14.3 months, respectively (P < 0.001). Performance status (P < 0.001), disease stage (P < 0.001) and pre-treatment LDH (P < 0.001) also significantly predicted OS. Multivariate analyses showed mGPS was an independent prognostic factor (P < 0.001). This study demonstrated that higher mGPS independently predicts worse OS for SCLC patients. The assessment of mGPS could assist the identification of patients with poor prognosis and be a hierarchical factor in the future SCLC clinical trials.
近期研究表明，C反应蛋白（CRP）与白蛋白联合使用（改良格拉斯哥预后评分，mGPS）在某些实体瘤中具有预后价值。然而，尚无研究探讨其在小细胞肺癌（SCLC）患者中的预后作用。在这项回顾性研究中，筛查了460例连续的SCLC患者。根据治疗前血浆CRP和白蛋白水平，将符合条件的患者的mGPS分为0、1或2（0：CRP≤10mg/L；1：CRP>10mg/L且白蛋白≥35g/L；2：CRP>10mg/L且白蛋白<35g/L）。进行单因素和多因素分析以评估SCLC相关因素的预后价值。共分析了359例患者。mGPS为0、1和2的患者分别占总患者的66.3%、30.6%和3.1%。mGPS为0、1和2的患者的中位总生存期（OS）分别为30.4、28.2和14.3个月（P<0.001）。体能状态（P<0.001）、疾病分期（P<0.001）和治疗前乳酸脱氢酶（P<0.001）也显著预测了OS。多因素分析显示mGPS是一个独立的预后因素（P<0.001）。这项研究表明，较高的mGPS独立预测SCLC患者较差的OS。mGPS评估有助于识别预后不良的患者，并成为未来SCLC临床试验中的一个分层因素。
